Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1989 1
2003 1
2004 2
2005 3
2006 5
2007 4
2008 4
2009 2
2010 5
2011 8
2012 6
2013 12
2014 15
2015 11
2016 15
2017 16
2018 12
2019 11
2020 8
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

121 results
Results by year
Filters applied: . Clear all
Page 1
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M, Ozaka M, Okano N, Sugimori K, Fukutomi A, Hara H, Mizuno N, Yanagimoto H, Wada K, Tobimatsu K, Yane K, Nakamori S, Yamaguchi H, Asagi A, Yukisawa S, Kojima Y, Kawabe K, Kawamoto Y, Sugimoto R, Iwai T, Nakamura K, Miyakawa H, Yamashita T, Hosokawa A, Ioka T, Kato N, Shioji K, Shimizu K, Nakagohri T, Kamata K, Ishii H, Furuse J; members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Morizane C, et al. Among authors: yanagimoto h. Ann Oncol. 2019 Dec 1;30(12):1950-1958. doi: 10.1093/annonc/mdz402. Ann Oncol. 2019. PMID: 31566666 Free article. Clinical Trial.
A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
Kanai M, Hatano E, Kobayashi S, Fujiwara Y, Marubashi S, Miyamoto A, Shiomi H, Kubo S, Ikuta S, Yanagimoto H, Terajima H, Ikoma H, Sakai D, Kodama Y, Seo S, Morita S, Ajiki T, Nagano H, Ioka T. Kanai M, et al. Among authors: yanagimoto h. Cancer Chemother Pharmacol. 2015 Feb;75(2):293-300. doi: 10.1007/s00280-014-2648-9. Epub 2014 Dec 5. Cancer Chemother Pharmacol. 2015. PMID: 25477010 Free article. Clinical Trial.
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M. Ueno H, et al. Among authors: yanagimoto h. J Clin Oncol. 2013 May 1;31(13):1640-8. doi: 10.1200/JCO.2012.43.3680. Epub 2013 Apr 1. J Clin Oncol. 2013. PMID: 23547081 Clinical Trial.
Assessment of lenvatinib treatment for unresectable hepatocellular carcinoma with liver cirrhosis.
Komatsu S, Yano Y, Sofue K, Kido M, Tanaka M, Kuramitsu K, Awazu M, Gon H, Yamamoto A, Yanagimoto H, Toyama H, Kodama Y, Murakami T, Fukumoto T. Komatsu S, et al. Among authors: yanagimoto h. HPB (Oxford). 2020 Oct;22(10):1450-1456. doi: 10.1016/j.hpb.2020.03.002. Epub 2020 Mar 29. HPB (Oxford). 2020. PMID: 32238302
Clinical Significance of Hepatectomy for Hepatocellular Carcinoma Associated with Extrahepatic Metastases.
Komatsu S, Kido M, Tanaka M, Kuramitsu K, Tsugawa D, Awazu M, Gon H, Yanagimoto H, Toyama H, Fukumoto T. Komatsu S, et al. Among authors: yanagimoto h. Dig Surg. 2020;37(5):411-419. doi: 10.1159/000507436. Epub 2020 May 26. Dig Surg. 2020. PMID: 32454487
Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma.
Yanagimoto H, Satoi S, Yamamoto T, Yamaki S, Hirooka S, Kotsuka M, Ryota H, Ishida M, Matsui Y, Sekimoto M. Yanagimoto H, et al. Cancers (Basel). 2020 May 31;12(6):1428. doi: 10.3390/cancers12061428. Cancers (Basel). 2020. PMID: 32486418 Free PMC article.
Quantitative immunohistochemical assay with novel digital immunostaining for comparisons of PD-L1 antibodies.
Fujisawa T, Tsuta K, Yanagimoto H, Yagi M, Suzuki K, Nishikawa K, Takahashi M, Okada H, Nakano Y, Iwai H. Fujisawa T, et al. Among authors: yanagimoto h. Mol Clin Oncol. 2019 Mar;10(3):391-396. doi: 10.3892/mco.2019.1801. Epub 2019 Jan 17. Mol Clin Oncol. 2019. PMID: 30847180 Free PMC article.
Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately.
Yoshida T, Hijioka S, Hosoda W, Ueno M, Furukawa M, Kobayashi N, Ikeda M, Ito T, Kodama Y, Morizane C, Notohara K, Taguchi H, Kitano M, Yane K, Tsuchiya Y, Komoto I, Tanaka H, Tsuji A, Hashigo S, Mine T, Kanno A, Murohisa G, Miyabe K, Takagi T, Matayoshi N, Sakaguchi M, Ishii H, Kojima Y, Matsuo K, Yoshitomi H, Nakamori S, Yanagimoto H, Yatabe Y, Furuse J, Mizuno N. Yoshida T, et al. Among authors: yanagimoto h. Ann Surg Oncol. 2019 May;26(5):1385-1393. doi: 10.1245/s10434-019-07252-8. Epub 2019 Mar 12. Ann Surg Oncol. 2019. PMID: 30863939
Reinforced staplers for distal pancreatectomy.
Kawai M, Hirono S, Okada KI, Satoi S, Yanagimoto H, Kon M, Murakami Y, Kondo N, Sho M, Akahori T, Toyama H, Fukumoto T, Fujii T, Matsumoto I, Eguchi H, Ikoma H, Takeda Y, Fujimoto J, Yamaue H. Kawai M, et al. Among authors: yanagimoto h. Langenbecks Arch Surg. 2017 Dec;402(8):1197-1204. doi: 10.1007/s00423-017-1634-1. Epub 2017 Nov 4. Langenbecks Arch Surg. 2017. PMID: 29103084 Clinical Trial.
Pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups.
Tanaka H, Hijioka S, Hosoda W, Ueno M, Kobayashi N, Ikeda M, Ito T, Kodama Y, Morizane C, Notohara K, Taguchi H, Kitano M, Komoto I, Tsuji A, Hashigo S, Kanno A, Miyabe K, Takagi T, Ishii H, Kojima Y, Yoshitomi H, Yanagimoto H, Furuse J, Mizuno N. Tanaka H, et al. Among authors: yanagimoto h. Pancreatology. 2020 Oct;20(7):1421-1427. doi: 10.1016/j.pan.2020.07.400. Epub 2020 Aug 8. Pancreatology. 2020. PMID: 32891532
121 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback